Stereotaxis (STXS) Investor presentation summary

Technology and innovation

• Offers unique robotic solutions for minimally invasive endovascular surgery, leveraging robotic magnetic navigation (RMN) for precise catheter control and improved safety in complex anatomies.

• GenesisX robot enables rapid installation and compatibility with various x-ray systems, reducing adoption barriers.

• Proprietary MAGIC ablation and mapping catheters expand the product portfolio and recurring revenue opportunities.

• Digital ecosystem launched with Synchrony Digital Operating Room System, integrating automation and AI for enhanced connectivity and workflow.

• Acquisition of Robocath and development of EMAGIN devices extend capabilities into interventional cardiology and neurointervention.

Market opportunity and commercial presence

• Addresses a total addressable market (TAM) exceeding $30B across electrophysiology, interventional cardiology, and neurointervention.

• Over 100 robotic systems installed in more than 20 countries, treating 150,000+ patients globally.

• Four major commercial opportunities identified: electrophysiology, interventional cardiology, neurointervention, and capital/SaaS models.

• Projected revenue growth from $32M in 2025 to $40M in 2026, driven by system sales, disposable catheters, and digital solutions.

Clinical and physician impact

• RMN technology delivers 72% fewer major complications, 36% less radiation exposure, and improved efficacy compared to manual procedures.

• Over 500 clinical publications validate safety, efficacy, and expanded treatment options for complex arrhythmias.

• Robotic approach reduces occupational hazards for physicians, enhances procedural control, and democratizes skill.